drugset / Trial / NCT04224545

COlchicine in Cardiac Surgery

NCT04224545

RandomizedParallel-groupTriple-blindTreatment

Summary

Postoperative atrial fibrillation (POAF) is a major complication of cardiac surgery, which could lead to high morbidity and mortality, increase duration of hospital stay and increase the cost of treatment. Colchicine possesses both anti-inflammatory and sympatholytic properties, so it has been studied to prevent POAF. The ACC/AHA guidelines for colchicine contain a class IIB recommendation, but the ESC guidelines do not recommend this drug. More researches are needed to focus on reducing of side effects by optimizing the colchicine regimen to reduce the incidence of gastrointestinal side effects. It is believed that further research is needed to investigate the efficacy and safety of colchicine in these conditions. This research is aimed to study the effectiveness of short-term administration of the drug.

Timeline

Start
2019-12-23
Primary completion
2022-08-15
Completion
2022-08-23

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Colchicine Small molecule 1 mg